Month: October 2013

Palatin Technologies Reports Successful Completion Of Device Bioequivalence Trial

CRANBURY, N.J., Oct. 28, 2013 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN) today announced the successful completion of a clinical trial designed to demonstrate equivalence of subcutaneously administered bremelanotide via autoinjector compared to pre-filled syringe administration. Bioequivalence was achieved in this clinical trial. Palatin used pre-filled syringes in its Phase 2 clinical trials, but will …

Palatin Technologies Reports Successful Completion Of Device Bioequivalence Trial Read More »

Palatin Technologies to Present at the 12th Annual BIO Investor Forum

CRANBURY, N.J., Oct. 4, 2013 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN) announced that it will be presenting at the 12th Annual BIO Investor Forum on Tuesday, October 8, 2013 at 3:30 p.m. Pacific Time.  Hosted by the Biotechnology Industry Organization (BIO), the 12th Annual BIO Investor Forum will take place October 8-9 at The …

Palatin Technologies to Present at the 12th Annual BIO Investor Forum Read More »

Scroll to Top